Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Christine Sanders
Institution:
University Hospital Bonn
Observed institution:
University Hospital Bonn
ORCID:
0009-0006-5886-1059
Observed ORCID:
0009-0006-5886-1059
OpenAlex ID:
A5060999105
The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
·
Molecular Cancer Therapeutics
·
9
Prognostic Significance of CD68+ Macrophages and FoxP3+ Regulatory T Cells in Neuroendocrine Tumors
2025
·
Markus Essler
, Glen Kristiansen
, et al.
·
Nuklearmedizin - NuclearMedicine
·
2
Figure S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
·
1
PDF
Data from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
Figure S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
PDF
Figure S3 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
PDF
Figure S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
PDF
Table S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
Table S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
Table S3 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
Table S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
Table S5 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
Table S7 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
Table S6 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025
·
Racha Hosni
, Niklas Klümper
, et al.
Low heterogeneity of tumor grades in multiple MRI-targeted prostate biopsies argues for the aggregate method of grading
2025
·
Oliver Hommerding
, Fereschte Sara Rejai
, et al.
·
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
PDF
Show more works
View as search
Works count:
15
Citation count:
12
H-index:
2
I10-index:
Year
Topic
Type